DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: KALETRA

Summary for Tradename: KALETRA

Patents:25
Applicants:1
NDAs:3
Suppliers: see list7
Formulation / Manufacturing:see details
drug
patent expirations by year for
 KALETRA

Clinical Trials for: KALETRA

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
Status: Completed Condition: HIV Infections

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Lopinavir Capsules to Kaletra or Invirase Tablets
Status: Completed Condition: HIV Infections

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
Status: Completed Condition: Antiretroviral Therapy in HIV-1 Infected Children

Lopinavir/Ritonavir (Kaletra) PK in Children
Status: Completed Condition: HIV/AIDS Treatment; HIV Infections

Evaluation of Kaletra Therapy Over the Long-term
Status: Completed Condition: Human Immunodeficiency Virus

GSK706769/KALETRA Drug-drug Interaction Study
Status: Completed Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
Status: Not yet recruiting Condition: AIDS; Tuberculosis

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
Status: Completed Condition: Pregnancy; HIV

Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
Status: Completed Condition: HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226Sep 15, 2000RXYes5,541,206*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226Sep 15, 2000RXYes5,648,497*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226Sep 15, 2000RXYes5,886,036*PED<disabled>Y<disabled>
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226Sep 15, 2000RXYes5,914,332*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: KALETRA

Drugname Dosage Strength RLD Submissiondate
lopinavir and ritonavirTablets100 mg/25 mgKaletra12/23/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc